Trastuzumab Injection: MedlinePlus Drug Information

trastuzumab  The results of this trial indicate that trastuzumab is active as a single agent and produces durable objective responses in women with HER2-overexpressing Trastuzumab ซึ่งสามารถลดอัตราการเสียชีวิตได้ถึง 24%และถ้าหากใช้ ยามุ่งเป้าชนิดต้าน HER2 – Trastuzumab กับ Pertuzumab ร่วมกับยาเคมีบำบัด จะสามารถลดอัตราการ

If you're having trastuzumab to treat primary breast cancer after surgery, it's usually given for 1 year Some people may be offered In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed

Trastuzumab belongs to class of monoclonal antibody It binds selectively to a protein called human epidermal growth factor receptor 2  In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed